Bayer to Advance Cell Therapy Manufacturing with $250M, All-Electric Facility
-
$250 million (USD) plant will help produce transformational cell and gene therapies on a global scale
-
Creating readiness for first production runs of potential commercial launches, including bemdaneprocel (BRT-DA01), BlueRock Therapeutics’ investigational cell therapy for Parkinson’s disease as well as product supply for late-stage clinical trials
-
New plant helps break industry-wide bottleneck in manufacturing capacity for regenerative medicines
-
100,000 sq. ft. building advances Bayer’s sustainability efforts – first fully electric manufacturing plant in Bayer’s global pharmaceutical manufacturing network
Novo Nordisk Sinks US $136M into Landmark Stem Cell Manufacturing Facility in Denmark
The Novo Nordisk Foundation will invest up to US$136 million in a new cell therapy manufacturing facility in Lyngby, Denmark.
The Novo Nordisk Foundation is making a substantial commitment of up to DKK 950 million (US $136M) to create an advanced facility dedicated to scaling up cell therapies for use in human patients. This facility, known as the Novo Nordisk Foundation Cellerator, is poised to address a critical gap in the Danish cell therapy ecosystem. Its overarching goal is to facilitate the transition from groundbreaking cell therapy research to tangible treatments for individuals grappling with various chronic diseases such as chronic heart failure, Parkinson’s disease, kidney disease, type 1 diabetes, and several forms of cancer. [Read more…]
Danaher’s Ventures Pours $18M into BlueWhale Bio, a Cell Therapy Manufacturing Company Co-founded by Carl June
-
BlueWhale Bio Science Team led by world-renowned immunotherapy pioneers Carl June and James Riley of University of Pennsylvania
-
BlueWhale Bio technology platform aims to bring cell and gene therapy benefits to patients faster and at lower cost
-
Investors include Danaher Ventures, Novalis LifeSciences, Marshall Wace, Hillhouse Capital
Celularity announces multi-year research collaboration services agreement with Regeneron
In major news that broke this morning, Celularity (CELU) has announced a partnership with Regeneron (REGN) to support the research, preclinical development, and manufacturing of allogeneic targeted cell therapy candidates targeting difficult-to-treat cancers.
The selection follows months of rigorous assessment and due diligence by Regeneron and showcases a high level of confidence and validation of Celularity’s core science, business model, and strategic vision. Celularity’s expertise in the off-the-shelf allogeneic cell therapy field is exceptional and includes the engineering and design of chimeric antigen receptors (CAR) for use with T and natural Killer (NK) cells. [Read more…]
- « Previous Page
- 1
- …
- 31
- 32
- 33
- 34
- 35
- …
- 63
- Next Page »